Print
MailOm ook met de Belgische particuliere belegger een goede dialoog te onderhouden, heeft Movetis de IR pagina's ook in het Nederlands uitgewerkt. Deze optie kan worden aangeklikt in de rechterstrook van deze pagina.
Movetis attaches great importance to a good relationship with its shareholders and fosters a transparent communication and a constructive dialogue with institutional and retail investors.
Movetis contact persons for investors and shareholders are Dirk Reyn (CEO), Catherine Moukheibir (CFO) and Chris Van Raemdonck (Communications Director), who is also the first-line contact (chris.vanraemdonck@movetis.com).
Key information for investors can be found through the menu on the left panel of this webpage. On the right panel investors can found the company's share price, and can also download the annual report.
Investors can download here the following, recently published, documents:
- Press release "Study results of prucalopride in elderly patients with chronic constipation are published in Neurogastroenterology and Motility" (28 June 2010)
- Press release "Movetis starts phase III clinical trial with prucalopride in patients with opioid induced constipation" (19 May 2010)
- Most recent presentation to investors
Recent events for investors:
- Presentation at VFB Biotech Day for retail investors, in Ghent (26 June 2010)
- Participation in Euro-Biotech Forum (Windhover conference) in Paris (28-30 June 2010)
- Earlier in 2010, Movetis visited investors in the London, Stockholm, Paris, Amsterdam, Brussels, Antwerp, Ghent, Zurich and San Francisco.
Upcoming events for investors:
- Publication of Half Year 2010 Results of Movetis (26 August 2010 - 5:45 PM CET)
- Participation in VFB retail investors conference (Antwerp, 2 October)
- Investor road show programme (including US in 2nd half of 2010)
